Document is current
Any future updates will be listed below
-
Authors
Woolpert, Kirsten M.
Schmidt, Julie A.
Ahern, Thomas P.
Hjorth, Cathrine F.
Farkas, Dóra K.
Ejlertsen, Bent
Collin, Lindsay J.
Lash, Timothy L.
Cronin-Fenton, Deirdre P.
-
Funding
Funding for this research was provided by:
National Cancer Institute (K99CA277580, R01CA166825)
Danmarks Frie Forskningsfond (DFF-1030-00052B)
Novo Nordisk (NNF19OC0058710)
Kræftens Bekæmpelse (R327-A19070)
- License Information
-
More Information
Article History
Received: 4 December 2023
Accepted: 2 April 2024
First Online: 8 April 2024
Declarations
:
: This study was approved by Central Denmark’s Regional Ethics Committee (journal number 1-10-72-22-13), the Danish Breast Cancer Group, the Danish Data Protection Agency (Aarhus University number 2016-051-000001, #458), and adhered to the General Data Protection Regulation. The data in this study was compiled and analyzed within the secure servers of Statistics Denmark in accordance with Danish privacy laws.
: Not applicable.
: Timothy L. Lash is a member of the Amgen Methods Advisory Committee, for which he receives consulting fees and travel support to advise on pharmaceutical epidemiology projects unrelated to the current manuscript. Bent Ejlertsen has received institutional grants from AstraZeneca, Eli Lilly, MSD, Novartis, Pfizer, and Roche, unrelated to the current manuscript. All other authors report no conflicts of interest.
